In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations

T. S. Krueger, E. A. Clark, David E. Nix

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Stenotrophomonas maltophilia has emerged as a significant pathogen in compromised patients, causing infections which are difficult to treat. Clinical isolates from patients in the Tucson area were tested against single and combination antibiotics using three testing methods. Ticarcillin/clavulanate, trimethoprim/sulfamethoxazole and trovafloxacin provided comparable inhibitory activity, in vitro. Ciprofloxacin, imipenem and ticarcillin were active less often. Agreements between disk diffusion and broth microdilution results were poor for ciprofloxacin and trimethoprim/sulfamethoxazole; however, agreement was ≥ 90% for the other drugs tested. Major or very major errors were observed with ticarcillin, ticarcillin/clavulanate, and trovafloxacin. The addition of aztreonam to ticarcillin/clavulanate enhanced the activity compared to ticarcillin/clavulanate alone using the double-disk diffusion, broth microdilution (checkerboard), and time-kill testing methods. Trovafloxacin exhibited good activity by all three methods, with bactericidal activity at ≥ 2× MIC. These results indicate that the newer fluoroquinolones or the triple combination of ticarcillin/clavulanate plus aztreonam may be potential options for treatment of infection caused by S. maltophilia in patients who are intolerant to or fail trimethoprim/sulfamethoxazole therapy.

Original languageEnglish (US)
Pages (from-to)71-78
Number of pages8
JournalDiagnostic Microbiology and Infectious Disease
Volume41
Issue number1-2
DOIs
StatePublished - 2001

Fingerprint

Stenotrophomonas maltophilia
Ticarcillin
Clavulanic Acid
Sulfamethoxazole Drug Combination Trimethoprim
Aztreonam
Ciprofloxacin
Imipenem
Fluoroquinolones
Infection
In Vitro Techniques
Anti-Bacterial Agents
Therapeutics

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. / Krueger, T. S.; Clark, E. A.; Nix, David E.

In: Diagnostic Microbiology and Infectious Disease, Vol. 41, No. 1-2, 2001, p. 71-78.

Research output: Contribution to journalArticle

@article{f96c3b6cd468421a9e189521b19c0d71,
title = "In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations",
abstract = "Stenotrophomonas maltophilia has emerged as a significant pathogen in compromised patients, causing infections which are difficult to treat. Clinical isolates from patients in the Tucson area were tested against single and combination antibiotics using three testing methods. Ticarcillin/clavulanate, trimethoprim/sulfamethoxazole and trovafloxacin provided comparable inhibitory activity, in vitro. Ciprofloxacin, imipenem and ticarcillin were active less often. Agreements between disk diffusion and broth microdilution results were poor for ciprofloxacin and trimethoprim/sulfamethoxazole; however, agreement was ≥ 90{\%} for the other drugs tested. Major or very major errors were observed with ticarcillin, ticarcillin/clavulanate, and trovafloxacin. The addition of aztreonam to ticarcillin/clavulanate enhanced the activity compared to ticarcillin/clavulanate alone using the double-disk diffusion, broth microdilution (checkerboard), and time-kill testing methods. Trovafloxacin exhibited good activity by all three methods, with bactericidal activity at ≥ 2× MIC. These results indicate that the newer fluoroquinolones or the triple combination of ticarcillin/clavulanate plus aztreonam may be potential options for treatment of infection caused by S. maltophilia in patients who are intolerant to or fail trimethoprim/sulfamethoxazole therapy.",
author = "Krueger, {T. S.} and Clark, {E. A.} and Nix, {David E.}",
year = "2001",
doi = "10.1016/S0732-8893(01)00281-4",
language = "English (US)",
volume = "41",
pages = "71--78",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations

AU - Krueger, T. S.

AU - Clark, E. A.

AU - Nix, David E.

PY - 2001

Y1 - 2001

N2 - Stenotrophomonas maltophilia has emerged as a significant pathogen in compromised patients, causing infections which are difficult to treat. Clinical isolates from patients in the Tucson area were tested against single and combination antibiotics using three testing methods. Ticarcillin/clavulanate, trimethoprim/sulfamethoxazole and trovafloxacin provided comparable inhibitory activity, in vitro. Ciprofloxacin, imipenem and ticarcillin were active less often. Agreements between disk diffusion and broth microdilution results were poor for ciprofloxacin and trimethoprim/sulfamethoxazole; however, agreement was ≥ 90% for the other drugs tested. Major or very major errors were observed with ticarcillin, ticarcillin/clavulanate, and trovafloxacin. The addition of aztreonam to ticarcillin/clavulanate enhanced the activity compared to ticarcillin/clavulanate alone using the double-disk diffusion, broth microdilution (checkerboard), and time-kill testing methods. Trovafloxacin exhibited good activity by all three methods, with bactericidal activity at ≥ 2× MIC. These results indicate that the newer fluoroquinolones or the triple combination of ticarcillin/clavulanate plus aztreonam may be potential options for treatment of infection caused by S. maltophilia in patients who are intolerant to or fail trimethoprim/sulfamethoxazole therapy.

AB - Stenotrophomonas maltophilia has emerged as a significant pathogen in compromised patients, causing infections which are difficult to treat. Clinical isolates from patients in the Tucson area were tested against single and combination antibiotics using three testing methods. Ticarcillin/clavulanate, trimethoprim/sulfamethoxazole and trovafloxacin provided comparable inhibitory activity, in vitro. Ciprofloxacin, imipenem and ticarcillin were active less often. Agreements between disk diffusion and broth microdilution results were poor for ciprofloxacin and trimethoprim/sulfamethoxazole; however, agreement was ≥ 90% for the other drugs tested. Major or very major errors were observed with ticarcillin, ticarcillin/clavulanate, and trovafloxacin. The addition of aztreonam to ticarcillin/clavulanate enhanced the activity compared to ticarcillin/clavulanate alone using the double-disk diffusion, broth microdilution (checkerboard), and time-kill testing methods. Trovafloxacin exhibited good activity by all three methods, with bactericidal activity at ≥ 2× MIC. These results indicate that the newer fluoroquinolones or the triple combination of ticarcillin/clavulanate plus aztreonam may be potential options for treatment of infection caused by S. maltophilia in patients who are intolerant to or fail trimethoprim/sulfamethoxazole therapy.

UR - http://www.scopus.com/inward/record.url?scp=0034777406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034777406&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(01)00281-4

DO - 10.1016/S0732-8893(01)00281-4

M3 - Article

VL - 41

SP - 71

EP - 78

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 1-2

ER -